Praxis Bioresearch Awarded $1.5 Million Fast-Track SBIR Grant for Development of Novel Prodrug Stimulant with Abuse-Deterrent Properties MENLO PARK, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...

Praxis Bioresearch Announces Peer-Reviewed Publication of Positive Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties MENLO PARK, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...

Praxis Bioresearch Presents Positive Preclinical Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties at ACNP Annual Meeting MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...